WGS and WES.
Genomic DNA was obtained from PBMCs before anti–PD-1 treatment. It was subjected to WGS on the Illumina HiSeq X Ten platform with the sequencing depth set to 50× (Illumina), and it was subjected to WES on the Illumina Novaseq 6000 platform with the sequencing depth set to 200× (Illumina). Genomic DNA from peripheral blood granulocytes was used as the germline control.